Literature DB >> 15729176

Liver transplantation for hepatocellular carcinoma in cirrhosis: is clinical tumor classification before transplantation realistic?

Georgios C Sotiropoulos1, Massimo Malagó, Ernesto Molmenti, Andreas Paul, Silvio Nadalin, Eirini Brokalaki, Hilmar Kühl, Olaf Dirsch, Hauke Lang, Christoph E Broelsch.   

Abstract

BACKGROUND: The decision of whether to proceed with transplantation in patients with hepatocellular carcinoma (HCC) in cirrhosis is based on clinical and imaging findings. The purpose of our study was to evaluate the accuracy of the current system.
MATERIALS AND METHODS: We evaluated data of 70 patients with HCC who underwent liver transplantation (LTx) at our center. We specifically analyzed the correlation between preoperative imaging studies and postoperative anatomopathologic findings. Tumor-node-metastasis, Milan, and University of California San Francisco (UCSF) classifications were used. Patients were divided in 2 groups: (1) Patients undergoing live-donor LTx (LDLTx, n=35) and (2) patients undergoing cadaveric LTx (CLTx, n=35).
RESULTS: Only 10 (14.3%) of the 70 patients considered had tumor diameter that was correctly identified by pretransplant radiologic examinations. Twenty-four (34.2%) patients had correct identification of the number of tumors present. Fifty (71.4%) patients had incorrect measurements of tumor diameter of more than 1 cm. Sensitivity of radiologic imaging was especially poor for tumors between 1 and 2 cm and less than 1 cm (21% and 0%, respectively). Best accuracy of 60% was found for both the Milan and UCSF criteria. No significant difference was found between the two patient groups concerning the accuracy of the various systems/criteria of classification.
CONCLUSIONS: Current imaging techniques have a high incidence of false-negative and false-positive results when evaluating HCC in cirrhosis. A critical appraisal of patient characteristics together with great caution when interpreting imaging studies is recommended to determine candidacy for transplantation.

Entities:  

Mesh:

Year:  2005        PMID: 15729176     DOI: 10.1097/01.tp.0000152801.82734.74

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  26 in total

1.  Liver transplantation for hepatocellular carcinoma on cirrhosis: strategies to avoid tumor recurrence.

Authors:  Marco Vivarelli; Andrea Risaliti
Journal:  World J Gastroenterol       Date:  2011-11-21       Impact factor: 5.742

2.  Preoperative alpha-fetoprotein slope is predictive of hepatocellular carcinoma recurrence after liver transplantation.

Authors:  Kathy Han; George N Tzimas; Jeffrey S Barkun; Peter Metrakos; Jean L Tchervenkov; Nir Hilzenrat; Phil Wong; Marc Deschênes
Journal:  Can J Gastroenterol       Date:  2007-01       Impact factor: 3.522

3.  Impact of preoperative α-fetoprotein level on disease-free survival after liver transplantation for hepatocellular carcinoma.

Authors:  Fabrice Muscari; Jean-Pascal Guinard; Nassim Kamar; Jean-Marie Peron; Philippe Otal; Bertrand Suc
Journal:  World J Surg       Date:  2012-08       Impact factor: 3.352

4.  Liver transplantation, liver resection, and transarterial chemoembolization for hepatocellular carcinoma in cirrhosis: which is the best oncological approach?

Authors:  Georgios C Sotiropoulos; Nina Drühe; George Sgourakis; Ernesto P Molmenti; Susanne Beckebaum; Hideo A Baba; Gerald Antoch; Philip Hilgard; Arnold Radtke; Fuat H Saner; Silvio Nadalin; Andreas Paul; Massimo Malagó; Christoph E Broelsch; Hauke Lang
Journal:  Dig Dis Sci       Date:  2008-12-05       Impact factor: 3.199

5.  Patients without hepatocellular carcinoma progression after transarterial chemoembolization benefit from liver transplantation.

Authors:  Aiman Obed; Alexander Beham; Kerstin Püllmann; Heinz Becker; Hans J Schlitt; Thomas Lorf
Journal:  World J Gastroenterol       Date:  2007-02-07       Impact factor: 5.742

6.  Hepatocellular Carcinoma in an HIV Patient "Cured" of Hepatitis C Virus.

Authors:  Arun Swaminath
Journal:  Gastroenterol Hepatol (N Y)       Date:  2006-08

Review 7.  Prediction of hepatocellular carcinoma biological behavior in patient selection for liver transplantation.

Authors:  Umberto Cillo; Tommaso Giuliani; Marina Polacco; Luz Maria Herrero Manley; Gino Crivellari; Alessandro Vitale
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

8.  Efficacy of contrast-enhanced FDG PET/CT in patients awaiting liver transplantation with rising alpha-fetoprotein after bridge therapy of hepatocellular carcinoma.

Authors:  Rania Refaat; Mohammad Abd Alkhalik Basha; Mohammed Sobhi Hassan; Rasha S Hussein; Ahmed A El Sammak; Dena Abd El Aziz El Sammak; Mohamed Hesham Saleh Radwan; Nahla M Awad; Somaia A Saad El-Din; Engi Elkholy; Dina R D Ibrahim; Shereen A Saleh; Iman F Montasser; Hany Said
Journal:  Eur Radiol       Date:  2018-06-12       Impact factor: 5.315

Review 9.  [Liver resection and transplantation for hepatic tumors].

Authors:  H Lang; C E Broelsch
Journal:  Internist (Berl)       Date:  2007-01       Impact factor: 0.743

10.  Comparison of hepatic resection and transarterial chemoembolization for solitary hepatocellular carcinoma.

Authors:  Dong-Zhi Zhang; Xiao-Dong Wei; Xiao-Peng Wang
Journal:  World J Gastroenterol       Date:  2015-04-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.